Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 3,045 Shares of Stock

Key Points

• Michael Burkes Brophy, CFO of Natera, Inc., recently sold 3,045 shares of the company at an average price of $137.40, totaling $418,383, and now holds 65,430 shares valued at approximately $8.99 million.
• Natera's stock price reached $140.96 during midday trading, showcasing a strong market presence with a market capitalization of $19.25 billion.
• Several analysts have raised their price targets for Natera, with Barclays setting a target of $190.00 and Piper Sandler moving to $210.00, reflecting ongoing optimism for the company's potential growth.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 3,045 shares of the company's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total value of $418,383.00. Following the transaction, the chief financial officer directly owned 65,430 shares in the company, valued at $8,990,082. The trade was a 4.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, July 28th, Michael Burkes Brophy sold 2,019 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $282,276.39.
• On Tuesday, July 22nd, Michael Burkes Brophy sold 920 shares of Natera stock. The shares were sold at an average price of $139.58, for a total value of $128,413.60.
• On Thursday, July 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The stock was sold at an average price of $139.50, for a total transaction of $105,322.50.
• On Wednesday, July 23rd, Michael Burkes Brophy sold 495 shares of Natera stock. The stock was sold at an average price of $141.28, for a total transaction of $69,933.60.
• On Monday, July 21st, Michael Burkes Brophy sold 602 shares of Natera stock. The stock was sold at an average price of $139.29, for a total transaction of $83,852.58.

Natera Stock Up 0.7%

Shares of NTRA stock traded up $0.92 during trading hours on Friday, hitting $134.58. 1,165,817 shares of the company's stock were exchanged, compared to its average volume of 1,493,227. The firm has a market cap of $18.38 billion, a P/E ratio of -91.55 and a beta of 1.73. The firm has a 50 day moving average of $157.54 and a two-hundred day moving average of $156.09. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same period in the prior year, the company posted ($0.56) EPS. The business's quarterly revenue was up 36.5% on a year-over-year basis. On average, equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of research analyst reports. Piper Sandler raised their price target on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Evercore ISI initiated coverage on Natera in a research report on Monday. They set an "outperform" rating and a $170.00 price objective for the company. UBS Group raised their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Barclays upped their price objective on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Finally, Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. One analyst has rated the stock with a sell rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $183.76.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently modified their holdings of the company. LRI Investments LLC acquired a new stake in shares of Natera in the 4th quarter valued at about $29,000. Bank of Jackson Hole Trust acquired a new position in Natera in the first quarter valued at $29,000. Rakuten Securities Inc. boosted its stake in shares of Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after buying an additional 119 shares during the period. ORG Partners LLC purchased a new position in shares of Natera during the first quarter worth about $32,000. Finally, TCTC Holdings LLC increased its position in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after acquiring an additional 124 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.